• RejuvenAir® Clinical Trial Information

    The RejuvenAir® System is undergoing clinical studies to ensure the safety and effectiveness of the treatment for chronic bronchitis patients. During the clinical studies, the procedure is limited to use by the clinical study sites under the clinical trial protocol.

     Safety and Feasibility Study of RejuvenAir for Treating Chronic Bronchitis Patients (Feasibility) (NCT0483637)

    DesignThis is a prospective, open label, multi-center, single arm clinical trial.
    Study PhaseFeasibility
    Study GoalsTo evaluate the safety of the RejuvenAir Cryospray Therapy to treat symptomatic chronic bronchitis patients with airflow restrictions and to evaluate the feasibility of planned liquid nitrogen cryospray treatment.
    Patient PopulationSubjects age 40-75 with known diagnosis of chronic bronchitis who despite being on optimal medication have daily symptoms of cough and sputum.
    Participating SitesUniversity Medical Center Groningen, Groningen, The Netherlands
    Principal Investigator: Dirk-Jan Slebos, MD
    Royal Brompton Hospital, London, England
    Principal Investigator: Pallav Shah, MD
    St. Paul’s Hospital, Vancouver, Canada
    Principal Investigator: Don Sin, MD
    ResultsPreliminary results will be presented at the European Respiratory Society (ERS) meeting in Milan, Italy on Sunday September 10, 2017.

     

    For updated information on this clinical study, please go to:

    RejuvenAir Feasibility Study

     

    The RejuvenAir® System is currently under clinical investigation and is not commercially available.